• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

有效地将药理学模型转化为预测治疗效果。

Translating pharmacology models effectively to predict therapeutic benefit.

机构信息

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

出版信息

Drug Discov Today. 2022 Jun;27(6):1604-1621. doi: 10.1016/j.drudis.2022.03.009. Epub 2022 Mar 15.

DOI:10.1016/j.drudis.2022.03.009
PMID:35304340
Abstract

Many in vitro and in vivo models are used in pharmacological research to evaluate the role of targeted proteins in a disease. Understanding the translational relevance and limitation of these models for analyzing a drug's disposition, pharmacokinetic/pharmacodynamic (PK/PD) profile, mechanism, and efficacy, is essential when selecting the most appropriate model of the disease of interest and predicting clinically efficacious doses of the investigational drug. Selected animal models used in ophthalmology, infectious diseases, oncology, autoimmune diseases, and neuroscience are reviewed here. Each area has specific challenges around translatability and determination of an efficacious dose: new patient-specific dosing methods may help overcome these limitations.

摘要

在药理学研究中,许多体外和体内模型被用于评估靶向蛋白在疾病中的作用。了解这些模型在分析药物处置、药代动力学/药效学(PK/PD)特征、机制和疗效方面的转化相关性和局限性,对于选择最适合研究药物的疾病模型和预测临床有效剂量非常重要。本文综述了在眼科、传染病、肿瘤学、自身免疫性疾病和神经科学中使用的选定动物模型。每个领域都存在可转化性和确定有效剂量方面的具体挑战:新的患者特异性给药方法可能有助于克服这些局限性。

相似文献

1
Translating pharmacology models effectively to predict therapeutic benefit.有效地将药理学模型转化为预测治疗效果。
Drug Discov Today. 2022 Jun;27(6):1604-1621. doi: 10.1016/j.drudis.2022.03.009. Epub 2022 Mar 15.
2
Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies.翻译:从临床试验角度解读非临床肿瘤学研究。
Clin Cancer Res. 2017 Feb 15;23(4):1080-1090. doi: 10.1158/1078-0432.CCR-16-1164. Epub 2016 Aug 22.
3
Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjects.LY2775240,一种选择性磷酸二酯酶-4 抑制剂,在非临床模型和健康受试者中的特征。
Clin Transl Sci. 2021 May;14(3):1037-1048. doi: 10.1111/cts.12968. Epub 2021 Feb 13.
4
Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.转化药物研究中基于机制的药代动力学-药效学(PK-PD)建模
Trends Pharmacol Sci. 2008 Apr;29(4):186-91. doi: 10.1016/j.tips.2008.01.007. Epub 2008 Mar 18.
5
Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.从基础到系统药效动力学模型的转变:皮质类固醇的经验教训。
Pharmacol Rev. 2020 Apr;72(2):414-438. doi: 10.1124/pr.119.018101.
6
Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society.在安全药理学中运用药代动力学/药效学模型以更好地界定安全范围:安全药理学会区域研讨会
Expert Opin Drug Saf. 2007 Jul;6(4):465-71. doi: 10.1517/14740338.6.4.465.
7
A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.一种用于预测马拉维若体内抗病毒活性的药代动力学-药效学疾病模型。
Clin Pharmacol Ther. 2005 Nov;78(5):508-19. doi: 10.1016/j.clpt.2005.07.010. Epub 2005 Sep 28.
8
PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology.非甾体抗炎药的药代动力学-药效学整合与药代动力学-药效学建模:原理及其在兽医药理学中的应用
J Vet Pharmacol Ther. 2004 Dec;27(6):491-502. doi: 10.1111/j.1365-2885.2004.00618.x.
9
Translating Pharmacokinetic and Pharmacodynamic Data into Practice.将药代动力学和药效学数据应用于实践。
Vet Clin North Am Exot Anim Pract. 2018 May;21(2):169-182. doi: 10.1016/j.cvex.2018.01.001.
10
Development of translational pharmacokinetic-pharmacodynamic models.转化药代动力学-药效学模型的开发。
Clin Pharmacol Ther. 2008 Jun;83(6):909-12. doi: 10.1038/clpt.2008.52. Epub 2008 Mar 26.

引用本文的文献

1
Intranasal amyloid model of Alzheimer's disease - potential opportunities and challenges.阿尔茨海默病的鼻内淀粉样蛋白模型——潜在机遇与挑战
Pharmacol Rep. 2025 Apr;77(2):425-433. doi: 10.1007/s43440-024-00692-4. Epub 2025 Jan 8.
2
The Role of Pharmacometrics in Advancing the Therapies for Autoimmune Diseases.药物计量学在推进自身免疫性疾病治疗中的作用。
Pharmaceutics. 2024 Dec 5;16(12):1559. doi: 10.3390/pharmaceutics16121559.
3
Pharmacokinetics-Pharmacodynamics Modeling for Evaluating Drug-Drug Interactions in Polypharmacy: Development and Challenges.
多药治疗中药物-药物相互作用的药代动力学-药效学建模:开发与挑战。
Clin Pharmacokinet. 2024 Jul;63(7):919-944. doi: 10.1007/s40262-024-01391-2. Epub 2024 Jun 18.
4
The estimation and translation uncertainties in applying NOAEL to clinical dose escalation.应用 NOAEL 进行临床剂量递增的估计和翻译不确定性。
Clin Transl Sci. 2024 Jun;17(6):e13831. doi: 10.1111/cts.13831.